Satricabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes ex vivo transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, satricabtagene autoleucel specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - Autologous Anti-Claudin18.2 CAR-T Cells - Autologous Anti-Claudin18.2-transduced T Lymphocytes CT041 - Autologous CAR-CLD18 T Cells - Autologous CAR-CLD18.2 T Cells - CT 041 - CT-041 - CT041 - Claudin18.2-redirected Autologous Cells - SATRICABTAGENE AUTOLEUCEL